GlassScriptPhysician profile
Lauren Macaluso
NPI 1689755449
$2,992.42
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $210 · 2021: $404 · 2022: $453 · 2023: $1,087 · 2024: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,145.11 | 2019-2024 | Tysabri, Vumerity |
| Emd Serono, INC. | $530.56 | 2022-2024 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $342.12 | 2021-2023 | |
| Tg Therapeutics, INC. | $243.84 | 2023 | |
| Mallinckrodt Enterprises LLC | $120.01 | 2019 | |
| Genentech USA, INC. | $103.00 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Acorda Therapeutics, INC | $94.18 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $88.24 | 2019-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $77.43 | 2020-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $72.83 | 2023 | Purified Cortrophin Gel |
| Tanabe Pharma America, INC. | $49.84 | 2023 | |
| Amgen INC. | $37.65 | 2024 | Uplizna |
| Supernus Pharmaceuticals, INC. | $25.62 | 2023 | Qelbree |
| Adlon Therapeutics L.P. | $21.81 | 2019 | |
| Abbvie INC. | $20.29 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $19.89 | 2024 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Macaluso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.